|
Aug 8
|
ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 8
|
iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates
|
|
Aug 5
|
iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
|
|
May 10
|
iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
|
|
May 10
|
iTeos Therapeutics Announces $120 Million Registered Direct Offering
|
|
May 10
|
iTeos shares jump on TIGIT update; Acelyrin swaps CEOs
|
|
Apr 7
|
iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
|
|
Mar 6
|
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
|
|
Mar 6
|
iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
|
|
Mar 5
|
iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024
|
|
Nov 27
|
Does iTeos Therapeutics, Inc. (ITOS) Have the Potential to Rally 283.59% as Wall Street Analysts Expect?
|
|
Sep 6
|
iTeos to Participate in Upcoming Investor Conferences
|